Singapore markets close in 2 hours 11 minutes

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.7800-0.0500 (-1.77%)
At close: 4:00PM EDT
Sign in to post a message.
  • H
    Hannibal
    The amount of shorts bashing here on Yahoo, reminds me of the months april / may earlier this year . You know, right before we went from 1,7$ to 9,80$ . They only come out if they're scared. We're good
  • B
    Bobbie
    Read the following before you get sucked in by Piesccofer99 on OCGN. I have said all along they will only make money on if they sell their vaccine to North America. Piescoffer99 jumped up and down and said I was wrong. Maybe he should learn to do some DD or at least learn how to read!

    3. Full rights to its COVID-19 vaccine
    Ocugen secured commercialization rights from Bharat Biotech for Covaxin only in the U.S. and Canada. Its terms with Bharat allow the company to keep 45% of the profits from any sales of the COVID-19 vaccine in those two markets.

    This ship has sailed. Too many with better results. Too late to the game for North Amereica.
  • P
    Piescoffer99
    Wow Quay has released a video today encouraging women to have regular mammograms. Has he forgotten he runs a company with shareholders?
  • M
    Manny
    Piescoffer99 comes here to pump OCGN. Unless their vaccine gets approved in the US they will not make any money on it. They only get paid if it makes money in the US. You already have tow vaccines approved here with two of them much better. He doesn't care about anyone but himself. He tries to lead rookies and those of low IQ into his money losing stock picks!

    Even if the pandemic continues for a year or two, other vaccines will likely continue to dominate the market in developed countries while Covaxin could, at best, carve out a very tiny share of this space. And whatever sales it generates will have to be shared with Bharat Biotech. Covaxin's best shot, in my view, is to make waves in countries where vaccines aren't as readily available.

    But that wouldn't help Ocugen. And to make matters worse, none of the company's other pipeline programs have even made it to a phase 2 study yet. Any regulatory setback related to Covaxin could send Ocugen's stock spiraling down. Putting all this together, this biotech stock does not look like a particularly attractive investment at the moment. Investors would do better to look elsewhere.
  • A
    Alec
    probably rock bottom price right now. I think even without news this will go up but with news this will sky rocket
  • P
    Pierre
    Hey Dr. Quay,
    While you are totally right about this mammogram testing, what does your message has to do with you being Atossa’s CEO ?
    You get paid yearly $ 1 M to run Atossa !
    When do we get your video about Atossa’s research program ?
  • M
    Maruthi
    Endoxifen is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group. It is an active metabolite of tamoxifen and has been found to be effective in patients that have failed previous hormonal therapies (tamoxifen, aromatase inhibitors, and fulvestrant). The prodrug tamoxifen is metabolized by the CYP2D6 enzyme to produce endoxifen and afimoxifene (hydroxytamoxifen).
    Astra's Tamoxifen has limitations. When ATOS Endoxifen in market, no one will buy Tamoxifen, that's why Astra is playing 😉
    We know how major companies play in markets. Just wait guy...we all will become rich with AtossaTherapeutics 👍
  • N
    Ninja Trader
    ATOS hitting bullish territory. If the trend line persists we can see upwards of $6-7 within the month.
  • r
    royce
    Red days are buying opportunities if you believe in the companies management and its pipeline
  • A
    Anthony
    ATOS//Where is James the "SNAPPER"//SNAP down 25%//LOL
  • a
    alan
    ok! on this side we have our resident. shorters!
  • M
    Maruthi
    Endoxifen is one of the best medicines in the world. Probably the institutions want to buy this share at low price.
    But we would see between $3 to $4 this week. Just wait for some company suddenly buy in millions.
  • a
    alan
    ok if anyone is interested in my take overall !! to repeat, this market will go up. LONG TERM ! short term, bad! quick rotating, sector to sector! world in. major disaray! U.S. and. CHINA. more so. US . has. MAJOR! MAJOR ! PROBLEMS. the only thing. IMO. holding this up is. HUGEE. MINEY, both by. Americans , and by. THE. US. monopoly. money ! we're going up but. also dependant on. Lower than normal INTREST rates! but. remember this market is a. money artificial pumped one !! there's not enough real. growth based on. need and production. JUST IMO. I DONT LIKE THIS. MARKET! as with me! I'm letting the big dogs do my bidding , my. ETFS. as I said. I'm. sitting, reinvesting! I'm. big into. TECH ETFS, and. oil, Nat, gas, pipelines! the later I doubled up on in last 7 months !! but I will trim this back, THATS. TRIM. at right time ! I'm. sitting with. ATOS, DID DOLLAR AVG, but as I mentioned to yall! don't bite off more then you can chew!! thanks for your indulgence! 🤔😄👍🇺🇸🤠
  • K
    Kris
    The shareholders have spoken. Management needs to show some real progress before diluting us and driving the SP down. Start the Phase 3 trials of Endoxifen and start to submit some NDA's. There is plenty of cash on the balance sheet already to fund the Phase 3 trials and keep the company going. The share increase did not make any sense with $146M already on the balance sheet.

    Management did not provide a good reason for the increase and that is why it was not voted on. The company does not need money. Maybe we will find out some more news as to why this was done in the first place. The company has enough cash to complete the trials. Get approval and then we can talk about increasing shares.
  • S
    Saad
    Only one cent to my target $2.72, it should rebound the question can it pass $3.94 this week, I doubt it we need good news for that.
  • a
    alan
    so. pie ! what does that tell you ! do you get the feeling this company is just a trinket on his key chain ? my gut feeling is , if this. elite over bloated head case DOSENT move quick enough, the things in. ATOS. pipeline will. dry up ! die on the vine ! be overshadowed by other more aggressive companies! this QUQY, is to self absorbed!! ATOSA. BETTER. be a buy out or this will just spin it's wheels.
  • B
    Bill
    Piescoffer99 please share with us your news stock pick. We can hardly wait.
    PSFE AEVA OCGN SAVA ATOS RMO this list is long and filled with your failures.
  • B
    Bubble
    I sold at 3.6$. Unfortunately, I do not see the reason to stay here for now. Maybe I come back in June, when the hype will start building up. But I am disappointed with the investors decision to vote NO. They clearly said if YES then BO/partnership/acquisition. Time will show who was right. They must have had plan B in case of NO, but I dont think it is anything in short term. Maybe I am wrong. But I took profit regardless + I think stagnation period is here. GL and be patient!
  • B
    Bill
    Piescoffer99 turned me into a short. Never made so much money going against every thing he goes long.
    Made a fortune, I mean millions shorting PSFE ATOS SAVA OCGN RMO. Please keep them coming Piescoffer99. I am starting to like you!
  • H
    Hannibal
    So just to repeat what i reacted to this weird little kiddo 'Bob'. If you are a trader, leave. If you are an investor, don't worry for like a second. Endoxifen is the most important play here. According to the schedule, Quay has 2 appointments with the FDA in Q4, (which is right now) so we will get an update on that before end of year. AT-301, or the 'Covid'-Nasal spray, well i am too a little bit disappointed about that one. Phase 2 would only last for 6 weeks, and was planned to begin late Q3. Still no news. (Probably because of the NO-vote). Nonetheless, important to know, this is a nasal spray that (if they succeed), will be worldwide used and sold in pharmacies. It prevents you from getting ANY virus... Influenza, Covid-19, delta variant, any future virus that still have to be created in chinese laboratories ;) ... The science behind it is brilliant. It targets the transport enzyms of your body itself, instead of the virus. It prevents the virus from being transported from the nose, to the lungs, where the actual infection takes place. So still time for that one. Covid is not going anywhere. Oh and Yes, Merck has created a pill against Covid-19. Very impressive... After you are tested positive on Covid 19, you have 50% less chance to be hospitalized if you take that pill. The Nasal spray is 99% effective to prevent you from being infected. If you invest, hang on and chill. If you trade, make some money elsewhere! GLTA